BP-198
BP-198 is a inhibitor and a SNIPER-class degrader targeting to SARS-CoV-2 main protease (Mpro) , with antiviral activity. BP-198 recruits the IAP ubiquitin ligase complex to degrade target proteins via the ubiquitin-proteasome system. BP-198 also degrades protease mutants resistant to Nirmatrelvir (HY-138687). BP-198 can be used in studies related to COVID-19.
(Pink: SARS-CoV ligand (HY-176442); Blue: IAP ligand (HY-176441); Black: linker (HY-W457968)).
For research use only. We do not sell to patients.
- Formula: C56H72F6N12O10S2
- Molecular Weight:1251.37
-
Storage:
Please store the product under the recommended conditions in the Certificate of Analysis.
To place orders, for customer services and technical support, please contact: MedChemExpress USA
Tel: 609-228-6898 E-mail: [email protected] [email protected]
-
Biological Activity
-
Chemical Information
- Purity & Documentation
- References
-
Help & FAQs
Biological Activity
Description
Cellular Effect
|
Cell Line
|
Type | Value | Description | References |
|---|---|---|---|---|
| Calu-3 | IC50 |
11.8 μM
|
Antiviral activity against SARS-CoV-2 Omicron BA.5 in human Calu-3 cells by reducing infectious viral titer measured via yield-based antiviral assay at 24 h post-infection.
Antiviral activity against SARS-CoV-2 Omicron BA.5 in human Calu-3 cells by reducing infectious viral titer measured via yield-based antiviral assay at 24 h post-infection.
|
40287552 |
| Calu-3 | IC50 |
11.4 μM
|
Antiviral activity against SARS-CoV-2 Omicron BA.5 in human Calu-3 cells by reducing viral genome copy number measured via quantitative RT-PCR at 24 h post-infection.
Antiviral activity against SARS-CoV-2 Omicron BA.5 in human Calu-3 cells by reducing viral genome copy number measured via quantitative RT-PCR at 24 h post-infection.
|
40287552 |
In Vitro
BP-198 (0.5-20 μM; 2-24 h) specifically degrades wildtype SARS-CoV-2 Mpro in HEK293T LVX Mpro-HiBiT reporter cells in a concentration- and time-dependent manner, achieving a 72% reduction in Mpro levels at 20 μM over 24 h[1].
BP-198 (1.25-10 μM; up to 70 h post-infection) exhibits enhanced antiviral activity against wildtype SARS-CoV-2 (VIC-01) in VeroE6/TMPRSS2 and Calu-3 cells, with 2.6-fold higher potency than its non-degrading control BP-206 at 70 h post-infection in VeroE6/TMPRSS2 cells (IC50 = 6.93 μM)[1].
BP-198 (Serial dilutions; 24 h post-infection) demonstrates enhanced antiviral activity against SARS-CoV-2 Omicron BA.5 in Calu-3 cells, with an IC50 of 11.8 μM for reducing infectious viral titer and 11.4 μM for reducing viral genome copy number, showing 2.1-fold higher potency than its non-degrading control BP-206[1].
BP-198 (Serial dilutions; 18 h post-infection) retains enhanced antiviral activity against nirmatrelvir-resistant SARS-CoV-2 Delta (E166V/L50F) in VeroE6/TMPRSS2 cells, with an IC50 of 12.7 μM and only a 25-fold reduction in potency relative to wildtype Delta, compared to a 261-fold reduction for Nirmatrelvir (HY-138687)[1].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
Chemical Information
-
Molecular Weight 1251.37
-
Formula C56H72F6N12O10S2
-
SMILES
C[C@@H](C(N[C@@H](C1CCCCC1)C(N2CCC[C@H]2C3=NC(C(C4=CC(OCCCN5N=NC(CSC(C)([C@H](NC(C(F)(F)F)=O)C(N6[C@H](C(N[C@H](C#N)C[C@@H]7CCNC7=O)=O)[C@]8([H])[C@](C8(C)C)([H])C6)=O)C)=C5)=CC=C4)=O)=CS3)=O)=O)NC.OC(C(F)(F)F)=O
-
Shipping
Room temperature in continental US; may vary elsewhere.
-
Storage
Please store the product under the recommended conditions in the Certificate of Analysis.
Purity & Documentation
References
Calculators
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
BP-198 Related Classifications
HY-176440 Related Classifications
Powered by Bioz
Keywords